{"id":4762,"date":"2025-10-10T15:17:22","date_gmt":"2025-10-10T12:17:22","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4762"},"modified":"2025-11-03T20:18:13","modified_gmt":"2025-11-03T17:18:13","slug":"wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332\/","title":{"rendered":"Klinische Phase-2-Studie zur Exon-Skipping-Therapie WVE-N531 f\u00fcr Duchenne-Muskeldystrophie beginnt"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Wave Life Sciences Ltd. gab auf seiner ClinicalTrials.gov-Website bekannt, dass im November 2025 eine klinische Phase-2-Studie von WVE-N531 (Exon 53 Skipping Therapy) mit 175 Teilnehmern in Jordanien und dem Vereinigten K\u00f6nigreich beginnen wird.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Inhaltsverzeichnis<\/h2><nav><ul><li><a href=\"#what-is-wve-n-531-exon-skipping-therapy\">Was ist die WVE-N531 Exon-Skipping-Therapie<\/a><\/li><li><a href=\"#wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">WVE-N531 Exon-Skipping-Therapie Phase 2 \u2013 NCT07209332<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">So nehmen Sie an der klinischen Studie WVE-N531 teil<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-wve-n-531-exon-skipping-therapy\">Was ist die WVE-N531 Exon-Skipping-Therapie<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>WVE-N531 ist eine experimentelle Exon-Skipping-Therapie, die als potenzielle Therapie f\u00fcr Patienten mit DMD entwickelt wird, bei denen Exon 53-Skipping empf\u00e4nglich ist.<\/strong> WVE-N531 wurde unter Verwendung der branchenf\u00fchrenden Oligonukleotidchemie-Modifikationen von Wave entwickelt, einschlie\u00dflich der PN-R\u00fcckgratchemie. WVE-N531 wurde von der US-amerikanischen Food &amp; Drug Administration als Orphan Drug und Rare Pediatric Disease eingestuft.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr lesen<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/de\/mutations-and-deletions-amenable-to-exon-53-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Mutationen und Deletionen, die f\u00fcr Exon 53-Skipping-Therapien bei Duchenne-Muskeldystrophie geeignet sind<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"847\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg\" alt=\"Mutationen und Deletionen, die f\u00fcr Exon 53-Skipping-Therapien bei Duchenne-Muskeldystrophie geeignet sind\" class=\"wp-image-4566\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg 847w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-248x300.jpg 248w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-768x929.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1270x1536.jpg 1270w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1693x2048.jpg 1693w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-10x12.jpg 10w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-347x420.jpg 347w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-150x181.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-300x363.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-696x842.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1068x1292.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1920x2323.jpg 1920w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping.jpg 1984w\" sizes=\"auto, (max-width: 847px) 100vw, 847px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">WVE-N531 Exon-Skipping-Therapie Phase 2 \u2013 NCT07209332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dies ist eine offene Verl\u00e4ngerungsstudie (OLE) der Phase 2 zur Bewertung der langfristigen Sicherheit, Vertr\u00e4glichkeit, Wirksamkeit, Pharmakokinetik und Pharmakodynamik (PD) durch potenzielle explorative Biomarker von intraven\u00f6sem (IV) WVE-N531 bei Patienten mit DMD, die an einer anderen Studie zu WVE-N531 teilgenommen haben.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienbeginn (voraussichtlich)<\/strong>: 2025-11<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Prim\u00e4rer Abschluss (gesch\u00e4tzt)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienabschluss (gesch\u00e4tzt)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Anzahl der Teilnehmer (gesch\u00e4tzt)<\/strong>: 175<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studientyp<\/strong>: Interventionell<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Standort<\/strong>: Jordanien, Vereinigtes K\u00f6nigreich<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienberechtigte Altersgruppen<\/strong>: Kind, Erwachsener, \u00e4lterer Erwachsener<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wichtigste Ein- und Ausschlusskriterien. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07209332\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07209332<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">So nehmen Sie an der klinischen Studie WVE-N531 teil<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Um an der klinischen Phase-2-Studie zur Exon-Skipping-Therapie WVE-N531 teilzunehmen, k\u00f6nnen Sie die unten stehenden Kontaktinformationen verwenden. <strong>Mehr erfahren<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/de\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">Wie kann ich an klinischen Studien zur Duchenne-Krankheit (DMD) teilnehmen?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Name<\/strong>: Klinische Operationen<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Telefonnummer<\/strong>: 855-215-4687<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-Mail<\/strong>: clinicaltrials@wavelifesci.com<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr lesen<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/de\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Klinische Studien zu Duchenne (Liste aller Forschungsarbeiten)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wave Life Sciences Ltd. announced on its ClinicalTrials.gov website that a phase 2 clinical trial of WVE-N531 (Exon 53 Skipping Therapy) will begin in November 2025 with 175 participants in Jordan and the United Kingdom. What is WVE-N531 Exon Skipping Therapy WVE-N531 is an investigational exon skipping therapy being developed as a potential therapy for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4769,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,155,154,328,422,153,327],"class_list":["post-4762","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-exon-53","tag-exon-53-skipping","tag-exon-53-skipping-therapy","tag-exon-53-treatment","tag-wave-life-sciences","tag-wve-n531"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4762"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4769"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}